Recently, the Jiangsu Provincial Department of Science and Technology announced the proposed projects in the 2023 Transformation of Scientific and Technological Achievements Special Fund. magAssist's "long-acting portable ECMO system R&D and industrialization" project was approved to enter the list, and officially approved on August 26 after the publicity period.
New Generation Extracorporeal Membrane Oxygenation (ECMO) System - BreathMo®
The Extracorporeal Membrane Oxygenation (ECMO) System has been widely used to treat critically ill patients as a "lifesaver" by clinicians during the pandemic. ECMO can build a last line of defense for lives and has important social value.
Approved product: New Generation Extracorporeal Membrane Oxygenation (ECMO) System - BreathMo®
Product introduction: BreathMo® is a new generation portable extracorporeal membrane oxygenation (ECMO) system developed by magAssist, commonly known as "artificial lung". It is mainly used to maintain the respiratory and circulation function of patients with severe cardiopulmonary failure, prolong their lives, and win precious time for the rescue of critically ill patients.
Product innovation: The new generation ECMO product - BreathMo® - is developed based on the third generation of active magnetic levitation drive technology. The mechatronics technology using computational fluid dynamics design and optimization technology, magnetic levitation, and the drive system completely eliminates mechanical friction, improves blood compatibility, and greatly increases the performance and safety of ECMO. The optimized flow path design increases the use time of the oxygenator to 2 times that of the current domestic imported equipment. Membrane filament configuration optimization technology greatly improves oxygen exchange efficiency, reduces flow path resistance, and makes the membrane oxygenation closer to the natural lung. At the same time, the ultra-portable design can meet more complex clinical scenarios. A number of groundbreaking innovations make BreathMo® a product with excellent blood compatibility, long-term performance, high flow rate, high respiration exchange ratio, and low resistance. BreathMo® truly realizes the localization of the whole system, filling the gap in China.
The approval of this project refers to the government's recognition of magAssist's long-standing commitment to innovative technologies leading the world. This special fund will help magAssist go further in R&D and industrialization of the new generation ECMO system. magAssist expects to drive the innovation and development of domestic high-end medical devices and help achieve the goal of domestic replacement of high-end medical devices.